Effect of Telitacicept on Transitional Regulatory B Cells in Patients With Systemic Lupus Erythematosus
NCT06137053 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50
Last updated 2023-11-21
Summary
The effect of Telitacicept treatment on the changes of transitional regulatory B lymphocyte T1, T2B cell subsets and plasma blasts and the expression levels of cytokines IL-10, IL-35, April and BAFF in SLE.
Conditions
- Telitacicept
- Systemic Lupus Erythematosus
- Therapy
Sponsors & Collaborators
-
Yanfeng Hou
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-11-01
- Primary Completion
- 2025-12-31
- Completion
- 2025-12-31
Countries
- China
Study Locations
More Related Trials
-
A Study of Telitacicept in Subjects With Childhood-onset Systemic Lupus Erythematosus
NCT05687526 ·Status: COMPLETED ·Phase: PHASE1
-
Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus
NCT05247203 ·Status: COMPLETED ·Phase: PHASE1
-
A Prospective Comparative Study Involving Multiple Units to Evaluate the Efficacy and Safety of Telitacicept and Belimumab in the Treatment of Systemic Lupus Erythematosus.
NCT07069972 ·Status: NOT_YET_RECRUITING
-
Efficacy and Safety of Telitacicept for Prevention of Flares in SLE Patients
NCT06394063 ·Status: RECRUITING ·Phase: NA
-
Immune Cell Subsets in SLE Patients Treated with Telitacicept
NCT06677801 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
A Study of Telitacicept in Lupus Nephritis
NCT05680480 ·Status: RECRUITING ·Phase: PHASE2
-
Exploring the Therapeutic Effect of Telitacicept on Lupus Erythematosus Complicated With Thrombocytopenia
NCT05929248 ·Status: UNKNOWN ·Phase: PHASE2
-
Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease
NCT07077486 ·Status: RECRUITING ·Phase: PHASE4
-
Comparing Efficacy and Safety of Telitacicept and Belimumab in Lupus Nephritis: A Retrospective Multicenter Cohort Study.
NCT07031674 ·Status: COMPLETED
-
A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)
NCT06456567 ·Status: WITHDRAWN ·Phase: PHASE3
-
T Regulatory Cells IN LUPUS NEPHRITIS
NCT06428539 ·Status: NOT_YET_RECRUITING
-
The Effect of Mycophenolate Mofetil and Cyclophosphamide on the Lymphocyte Subsets in Patients With Proliferative Lupus Nephritis
NCT02954939 ·Status: RECRUITING ·Phase: NA
-
A Clinical Study of YTS109 Cell in R/R Systemic Lupus Erythematosus
NCT06943937 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)
NCT05306574 ·Status: TERMINATED ·Phase: PHASE3
-
Clinical Trial of TQB3702 Tablets in Subjects With Systemic Lupus Erythematosus (SLE)
NCT06859931 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus
NCT01764594 ·Status: COMPLETED ·Phase: PHASE1
-
Can Targeted Elimination of B-cell Depletion Therapy and/or Combination Therapy on Systemic Lupus Erythematosus
NCT00556192 ·Status: COMPLETED ·Phase: PHASE2
-
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus
NCT02535689 ·Status: COMPLETED ·Phase: PHASE1
-
The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment
NCT07340463 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus
NCT02725515 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)
NCT04305197 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of CAR-T Cells in Subjects With Systemic Lupus Erythematosus
NCT06900764 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Exploring Biomarkers for Therapeutic Response of Lupus Nephritis Based on Multi Omics Analysis
NCT06167174 ·Status: RECRUITING
-
The Efficacy and Safety of Telitacicept and Belimumab in Active Lupus Nephritis in the Real World: a Prospective Cohort Study
NCT05588830 ·Status: UNKNOWN
-
Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE
NCT01702038 ·Status: WITHDRAWN ·Phase: PHASE2